Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with strong clinical development results, particularly in weight loss and body composition improvements. The Q&A highlights robust plans for higher dose studies and formulation advancements, addressing analyst concerns. Despite some management vagueness, the strategic focus on safety, efficacy, and future milestones aligns with market optimism. The combination therapy's success and ongoing R&D efforts suggest potential stock price appreciation.
Key Financial Performance
Cash, cash equivalents, and short-term investments $25.7 million as of the end of 2025, managed to extend the runway through Q4 2026.
Weight loss in combination therapy (nimacimab + semaglutide) 22.3% mean weight loss at 52 weeks with no plateau observed, a 3% improvement over semaglutide alone at 26 weeks. Reasons include the combination's clinically meaningful signal and consistent mechanism.
Weight regain after therapy Participants on semaglutide alone regained 38.7% of weight over 13 weeks, while those on nimacimab + semaglutide regained only 17.8%. The reason is nimacimab's orthogonal mechanism driving durable weight loss.
Body composition during weight regain Participants on nimacimab + semaglutide maintained fat mass loss, while lean mass gain was the main driver of weight regain. This suggests nimacimab's mechanism supports better body composition outcomes.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nimacimab: Developed as a complementary therapy to GLP-1s for obesity treatment. Demonstrated 22.3% mean weight loss in combination with semaglutide over 52 weeks. Showed favorable safety profile with no neuropsychiatric signals and minimal GI burden. Expansion study initiated to evaluate higher doses and subcutaneous delivery using Halozyme's ENHANZE technology.
Antibody Peptide Conjugate (APC) Program: Introduced as a new product category combining nimacimab's mechanism with GLP receptor agonist in a single therapeutic. Demonstrated additive weight loss in preclinical studies and aims to simplify dosing while maintaining efficacy.
Positioning of Nimacimab: Positioned as a second-line add-on therapy for GLP-1 experienced patients who need additional weight loss. Targets unmet needs in the anti-obesity market, focusing on durability, tolerability, and body composition quality.
CBeyond Expansion Study: Initiated to generate safety and PK data at higher doses of nimacimab. Includes new intravenous cohorts and collaboration with Halozyme for subcutaneous delivery.
FDA Feedback: Received Type C meeting minutes providing guidance on Phase IIb trial design and combination therapy development.
Cost Management: Aligned cost structure to extend financial runway through Q4 2026, with $25.7 million in cash and investments.
Strategic Focus on Combination Therapies: Emphasizes nimacimab as an add-on therapy rather than competing with first-line incretins. Focuses on unmet needs in the GLP-1 experienced patient segment.
Platform Development: Developing a bioconjugation-enabled antibody platform for multi-mechanism metabolic combinations, starting with nimacimab as the initial scaffold.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory alignment and target product profile: The company is working on regulatory alignment and refining the target product profile, which could pose challenges if regulatory expectations are not met or if the product profile does not align with market needs.
Dose optimization and safety: The need to confirm safety and pharmacokinetics (PK) at higher doses of nimacimab presents a risk, as higher doses may lead to unforeseen safety issues or adverse effects.
Subcutaneous delivery feasibility: The company is working on enabling a practical higher exposure subcutaneous delivery, which could face technical or logistical challenges.
FDA feedback and Phase IIb trial design: The company is incorporating FDA feedback into the Phase IIb trial design, and any misalignment with regulatory expectations could delay the trial or impact its success.
Market competition: The anti-obesity medicine market is crowded and increasingly price-compressed, which could limit nimacimab's market penetration and profitability.
Combination therapy development: Developing nimacimab as a complementary add-on therapy alongside GLP-1s involves complexities, including ensuring incremental efficacy without sacrificing tolerability.
Capital management: The company is managing its operating plan to extend its financial runway through Q4 2026, but any unforeseen expenses or delays could strain resources.
Weight regain and durability: While nimacimab shows potential for durable weight loss, the risk remains that it may not meet expectations for long-term efficacy or durability in real-world settings.
Bioconjugation platform development: The development of the antibody peptide conjugate (APC) program is in early stages, and any setbacks could impact the company's long-term platform value.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
CBeyond Expansion Study: The study aims to rapidly generate safety and pharmacokinetic (PK) data at higher exposures (400 mg and 600 mg IV doses) to inform future clinical trials. The expansion will monitor for neuropsychiatric events and ensure safety through an independent Data Monitoring Committee (DMC).
Phase IIb Clinical Trial: The company is refining the Phase IIb clinical trial design based on FDA feedback, focusing on dose, duration, endpoints, and inclusion criteria. The trial will evaluate nimacimab as a complementary add-on therapy to GLP-1s, particularly for patients needing additional weight loss.
Nimacimab Development: Plans include developing a high-concentration nimacimab formulation (up to 200 mg/ml) and exploring next-generation nimacimab with extended half-life through Fc domain modifications. The goal is to improve dose convenience and reduce injection volume.
Antibody Peptide Conjugate (APC) Program: Early data shows promising results for a unimolecular dual mechanism biologic combining nimacimab with a GLP receptor agonist. The APC program aims to simplify dosing while maintaining efficacy.
FDA Feedback and Regulatory Alignment: The FDA provided feedback on the proposed Phase IIb trial design and potential registration path, helping to refine the protocol and align with regulatory expectations for combination therapies.
Market Positioning: Nimacimab is positioned as a second-line add-on therapy for GLP-1 experienced patients, addressing unmet needs such as weight loss plateaus, durability, and body composition quality.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about your plans to share data from the higher dose cohorts above 200 milligrams?
A:The company is expanding into Part C of the CBeyond study, aiming to generate data on higher doses before the end of the year, with updates expected in Q4 2026. The goal is to achieve a clear PK step-up, maintain CNS sparing safety, and demonstrate monotherapy activity consistent with exposure response.
Q:What is the status of your formulation work using the Halozyme technology?
A:The co-formulation work with ENHANZE is ongoing and expected to be ready for the Phase IIb study. The mix and deliver approach will be used initially, with plans for a prefilled syringe or auto-injector format for Phase III. The company is working closely with Halozyme and the FDA to meet requirements.
Q:Do you need to have that formulation available at higher doses before proceeding to Phase IIb?
A:No, the formulation work is being conducted in parallel with the execution of Phase IIb, and the auto-injector component will be ready for Phase III.
Q:When it comes to the expansion, do you think you're going high enough? Is there a reason to explore maybe even higher doses of nimacimab?
A:The selected doses are believed to be sufficient based on robust preliminary models and biodistribution data. Higher doses are being evaluated, but the current doses are expected to achieve meaningful inhibition and maintain safety.
Q:What do you see as the profile for the new program? Is the goal to improve in safety, efficacy, or both?
A:The new program is treated as long-term optionality, focusing on safety and efficacy improvements. It aims to leverage favorable half-life and safety while exploring metabolic modulators beyond GLP-1 receptor agonists. More updates will be provided later in the year.
Q:How do you think about which peripheral tissues are the most important for nimacimab's clinical effect? Does that differ between monotherapy and combination therapy?
A:Adipose tissue and liver are critical for monotherapy, focusing on lipid metabolism and glycemic control. In combination therapy, the focus may shift to enhanced energy expenditure and body composition changes, with less emphasis on hormone-regulating peptides.
Q:Why are you choosing to use IV in this Part C phase of the study instead of using ENHANZE?
A:IV provides the cleanest and fastest way to generate high exposure PK and safety data. ENHANZE will be ready for Phase IIb, but using IV allowed the expansion study to start sooner.
Q:For the expansion study, Part C, what is the basis for the equivalence between 400-milligram IV and 600 or 700 milligram subcutaneous?
A:The equivalence is based on a bioavailability study showing subcutaneous dosing has a relative bioavailability of about 56% compared to IV. The correct equivalent dose is closer to 700 milligrams.
Q:How long will the infusion time be for the IV formulation in Part C?
A:The infusion time for the IV formulation will be about an hour, with patients staying on-site longer for safety evaluations during the first few doses.
Q:What do you see as the bar for success from the expanded study as far as the dose to be taken forward for monotherapy?
A:The bar for success is primarily PK and safety data, with modest emerging signals of monotherapy activity at higher exposure validating the model. This will help finalize Phase IIb dosing.
Q:Do you still plan to share the full extension data with the 300 mg monotherapy patients?
A:The 300 mg dose data will be used to improve PK model sensitivity and exposure response curve but is not expected to define the commercial efficacy zone. The data will be shared as part of PK modeling.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the specific efficacy expectations for the 300 mg dose, stating it would not define the commercial intent of the efficacy zone. Additionally, they deferred detailed discussions on the new program's profile, promising updates later in the year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APC
Accounting Officer
CBeyond
CEO Principal
GLP receptor
IC concentration
IV
Officer Director
Phase IIb
Principal Accounting
Punit
RD
base
biodistribution
biology
conjugate
day
engagement
expansion
kg
milligram nimacimab
milligram weekly
nimacimab mechanism
nimacimab semaglutide
outcome
participant
path
peptide
plateau
rationale
receptor agonist
safety PK
serum
signal
therapeutic
tissue
week nimacimab
SKYE Transcript
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call presents a positive outlook with strong clinical development results, particularly in weight loss and body composition improvements. The Q&A highlights robust plans for higher dose studies and formulation advancements, addressing analyst concerns. Despite some management vagueness, the strategic focus on safety, efficacy, and future milestones aligns with market optimism. The combination therapy's success and ongoing R&D efforts suggest potential stock price appreciation.
Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call reveals mixed signals. Financial performance shows increased R&D expenses and a larger net loss, but cash reserves are solid. Product development is promising, with positive feedback on Nimacimab and its potential in obesity treatment. However, uncertainties remain, particularly regarding weight regain issues and the need for higher dosing. The Q&A session highlighted optimism about future trials but also exposed gaps in understanding current data. Overall, the financial health and product prospects balance out, leading to a neutral sentiment.
Skye Bioscience, Inc. (SKYE) CBeyond Phase 2a Clinical Trial Topline Data Conference Call Transcript
Neutral10-6
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
SKYE Slides
SKYE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
